SIBN SI-BONE, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1459839 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY37.1%
TTM EPS YoY39.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin79.4%
Operating margin-7.6%
Net margin-6.2%
FCF margin-1.9%
EBITDA margin-4.6%
Returns
ROE-7.7%
ROA-5.6%
ROIC (approx.)-7.2%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets28.1%
Debt / equity0.19x
Current ratio7.58x
Interest coverage-6.88x
Cash quality & payout
Operating cash flow / net income-0.44x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $200.93M | $167.18M |
| Cost of revenue | $41.05M | $35.06M |
| Gross profit | $159.88M | $132.12M |
| R&D expense | $17.45M | $16.56M |
| SG&A expense | $40.54M | $33.76M |
| Operating income | -$22.33M | -$35.25M |
| Interest expense | $2.63M | $3.44M |
| Pretax income | -$19.09M | -$31.08M |
| Income tax | $0 | $0 |
| Net income | -$18.90M | -$30.91M |
| EBITDA | -$16.56M | -$30.87M |
| EPS (basic) | -0.44 | -0.75 |
| EPS (diluted) | -0.44 | -0.75 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 42.96M | 41.47M |
| Balance sheet | ||
| Cash & equivalents | $42.24M | $34.95M |
| Receivables | $29.91M | $27.46M |
| Inventory | $33.90M | $27.07M |
| Current assets | $216.12M | $207.78M |
| PP&E, net | $21.30M | $20.37M |
| Total assets | $238.56M | $230.44M |
| Current liabilities | $25.28M | $27.13M |
| Long-term debt | $35.57M | $35.45M |
| Total debt | $35.57M | $35.45M |
| Total liabilities | $61.02M | $63.47M |
| Shareholders' equity | $177.53M | $166.96M |
| Net debt | -$6.67M | $504,000 |
| Shares outstanding | 43.65M | 42.09M |
| Cash flow statement | ||
| Operating cash flow | -$675,000 | -$12.43M |
| Capital expenditure | $8.41M | $10.50M |
| Free cash flow | -$9.09M | -$22.92M |
| Investing cash flow | $4.16M | $12.62M |
| Financing cash flow | $3.38M | $1.96M |
| Depreciation & amortization | $5.77M | $4.38M |
| Stock-based compensation | $25.52M | $25.87M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.